Provided by Tiger Trade Technology Pte. Ltd.

Kura Oncology

8.06
-0.2650-3.19%
Volume:99.70K
Turnover:813.49K
Market Cap:711.50M
PE:-2.53
High:8.29
Open:8.23
Low:8.06
Close:8.32
52wk High:12.49
52wk Low:5.41
Shares:88.33M
Float Shares:63.99M
Volume Ratio:1.22
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1784
EPS(LYR):-3.1784
ROE:-94.82%
ROA:-25.33%
PB:4.09
PE(LYR):-2.53

Loading ...

Kura Oncology Announces Positive Phase 1b Results for Ziftomenib Combination in Acute Myeloid Leukemia

Reuters
·
Nov 03, 2025

Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting

GlobeNewswire
·
Nov 03, 2025

Is Kura Oncology (NASDAQ:KURA) Weighed On By Its Debt Load?

Simply Wall St.
·
Nov 03, 2025

Kura Oncology Inc. to Release Third Quarter 2025 Financial Results

Reuters
·
Oct 29, 2025

Kura Oncology’s Ziftomenib Study: A Potential Game-Changer in Leukemia Treatment

TIPRANKS
·
Oct 28, 2025

Kura Oncology’s Competitive Edge in AML Treatment: Favorable Safety Profile of Ziftomenib Drives Buy Rating

TIPRANKS
·
Oct 27, 2025

Kura Shares up 2.3% After Co Receives $30 Mln Milestone Payment on Trial Development

THOMSON REUTERS
·
Oct 24, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Cipher Mining, Kura, GrafTech

Reuters
·
Oct 24, 2025

Kura Oncology Receives $30M Milestone Payment

TIPRANKS
·
Oct 24, 2025

Kura Oncology Receives $30 Million Milestone Payment for Ziftomenib AML Program

Reuters
·
Oct 24, 2025

Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib Aml Program With Kyowa Kirin

THOMSON REUTERS
·
Oct 24, 2025

Kura Oncology Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 20, 2025

Kura Oncology announces preliminary data from FTI programs

TIPRANKS
·
Oct 20, 2025

Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (AVBP) and Kura Oncology (KURA)

TIPRANKS
·
Oct 20, 2025

Kura Oncology Reports Promising Early Results for Darlifarnib in Combination Cancer Therapy

Reuters
·
Oct 18, 2025

Leerink Partners Reaffirms Their Buy Rating on Kura Oncology (KURA)

TIPRANKS
·
Oct 14, 2025

Bank of America Securities Keeps Their Buy Rating on Kura Oncology (KURA)

TIPRANKS
·
Oct 13, 2025

BRIEF-Kura Oncology Reports Inducement Grants

Reuters
·
Oct 03, 2025

Kura Oncology reports inducement grants under Nasdaq listing rule

TIPRANKS
·
Oct 03, 2025

Kura Oncology Grants Stock Options to New Employees Under 2023 Inducement Plan

Reuters
·
Oct 03, 2025